GRI Bio (NASDAQ:GRI) stock is falling on Wednesday after the clinical-stage biopharmaceutical company announced a proposed public offering for its shares.GRI Bio plans to offer up to 2,238,806 shares of GRI stock. Each of these shares comes with one Series C-1 warrant and one Series C-2 warrant. Each of these can be exercised for another share of GRI.GRI Bio doesn’t have a firm price ready for its public offering just yet. Instead, it’s operating off of an assumed price of $2.68 per share. This is also the ...